Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review-Reference-Cited by-同舟云学术

Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review

Published:2017-05-31 Issue:7 Volume:17 Page:725-736
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Eltobgy Mostafa¹,Oweira Hani²³⁴,Petrausch Ulf⁵,Helbling Daniel⁶,Schmidt Jan³,Mehrabi Arianeb⁴,Schöb Othmar³,Giryes Anwar²,Decker Michael⁷,Abdel-Rahman Omar⁸^ORCID

Affiliation:

1. Faculty of Medicine, Ain Shams University, Cairo, Egypt

2. Department of Oncology, Swiss Cancer Institute, Cham, Switzerland

3. Surgical Center Zurich, Hirslanden Hospital Zurich, Zurich, Switzerland

4. Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany

5. OncoCentrum Zurich, Swiss Tumor Immunology Institute (SwissTII), Zurich, Switzerland

6. OncoCentrum Zurich, Gastrointestinal Tumor Center Zurich (GITZ), Zurich, Switzerland

7. Department of Oncology, Zentrum für Integrative Onkologie, Zurich, Switzerland

8. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2017.1336088

Reference56 articles.

1. Cancer immunotherapy: moving beyond current vaccines

2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

3. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

4. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society;Multiple Sclerosis Journal;2024-02-15

2. Toxicities associated with immune checkpoint inhibitors: a systematic study;International Journal of Surgery;2023-05-03

3. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years;Frontiers in Immunology;2023-03-16

4. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system;Immunotherapy;2021-12

5. A case of meningoencephalitis that developed during nivolumab use;Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics;2021-10-25